<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598609</url>
  </required_header>
  <id_info>
    <org_study_id>SEPREVEN</org_study_id>
    <nct_id>NCT02598609</nct_id>
  </id_info>
  <brief_title>An Educational Program to Prevent Adverse Events in Neonates : a Randomised Trial.</brief_title>
  <acronym>SEPREVEN</acronym>
  <official_title>An Multifaceted Educational Program for Caregivers to Prevent Adverse Events in Neonatal Intensive Care Unit Patients, a Stepped Wedge Cluster Randomised Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Caeymaex Laurence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Paris 12 Val de Marne University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adverse events are frequent in Neonatal Intensive Care Units' (NICU) patients and account for
      a high morbidity and mortality. Possible severe adverse events are central line associated
      bloodstream infections (CLABSI), ventilator and catheter associated adverse events and
      medication errors. Severity of the patient's outcome after an adverse event can be classified
      using the National Coordinating Council for Medication Error Reporting and Preventing (NCC
      MERP) Index for categorizing medication errors.

      The study will test the hypothesis that rates of adverse events in NICU patients will be
      reduced by the implementation of an educational program for the NICU caregivers (nurses and
      physicians), consisting of strategies for recognizing and preventing adverse events in their
      unit. These strategies will be oriented to prevent CLABSI, medication errors, skin and nasal
      complications and ventilator and catheter-associated adverse events.

      This trial has a stepped wedge cluster design, in which the NICUs from 12 hospitals in France
      will be randomized to the timing of implementation of the educational program.

      In order to describe the adverse events occurring during the study period, an anonymous
      voluntary adverse event reporting system will be provided to the caregivers of the
      participating units. A nested study will examine how caregivers communicate with the
      patients' parents in case of adverse event (disclosure or not, and caregivers' reasons).

      The rates of adverse events will be measured retrospectively using a neonatal NICU trigger
      tool.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of adverse events/1000 patient-days</measure>
    <time_frame>4 to 18 months</time_frame>
    <description>Assessment of the effectiveness of the program on reducing the rates of adverse events (number of adverse events/1000 patient-days) (AEs) measured using a retrospective chart review with a NICU trigger tool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of preventable adverse events/1000 patient-days</measure>
    <time_frame>20 months</time_frame>
    <description>Assessment of the effectiveness of the program on reducing the rates of preventable adverse events (number of adverse events/1000 patient-days) (AEs) measured using a retrospective chart review with a NICU trigger tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of CRBSI/1000 catheter-days in the 12 participating NICUs in France</measure>
    <time_frame>20 months</time_frame>
    <description>Assessment of the effectiveness of the program on reducing the rates of Central line associated blood stream infections measured prospectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of unplanned extubations/100 ventilator-days in the 12 participating NICUs in France</measure>
    <time_frame>20 months</time_frame>
    <description>Assessment of the effectiveness of the program on reducing the rates of unplanned extubations collected prospectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of medication errors/1000 patient-days in the 12 participating NICUs in France</measure>
    <time_frame>20 months</time_frame>
    <description>Assessment of the effectiveness of the program on reducing the rates of medication errors collected prospectively and using the retrospective trigger tool chart review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Severity of outcome after the adverse events occurred in the 12 participating NICUs in France</measure>
    <time_frame>20 months</time_frame>
    <description>Describe the severity of outcome after different types of adverse events, with a prospective grading of severity using the MCC MERP Categorizing Index for each collected adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of types of adverse events occurring in NICU patients in France</measure>
    <time_frame>20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatitis score results before and after the use of antiseptic in neonates born less than 32 weeks of gestational age and aged less than 15 days. Prospective description of antisepsis procedure used (prospective multiple choice questionnaire).</measure>
    <time_frame>20 months</time_frame>
    <description>Prospective dermatitis score by the nurse in care of the patient, performed before and after cutaneous antisepsis for central line insertion, in the first 15 days of life if born before 32 weeks of gestational age. Rates of dermatitis scores passing from 0 or 1 (no dermatitis) to score 2 and more before and after antisepsis, according to antisepsis procedure and patient's characteristics (age and gestational age at birth).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Nasal scores results during the use of noninvasive nasal ventilation interfaces in neonates born less than 32 weeks of gestational age and aged less than 15 days</measure>
    <time_frame>20 months</time_frame>
    <description>Prospective nasal score by the nurse in care of the patient, performed in the first week of nasal ventilation (after extubation or not) if less than 15 days of age and if born before 32 weeks gestational age. Rates and type of nasal lesions according to interface and patient's characteristics (age and gestational age at birth).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of characteristics of disclosed and undisclosed adverse events to the patients' parents, caregivers' motivations, and perceived parental reactions</measure>
    <time_frame>20 months</time_frame>
    <description>For each collected adverse event, caregivers self-administered written questionnaire assessing of adverse event has been told to parent(s), heath care professional's reasons to disclosure it or not, and in case of disclosure, parental reactions according to health care professional (multiple choices)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economical impact of the program</measure>
    <time_frame>20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of severe extravasation injuries and evolution (context and rate per patients)</measure>
    <time_frame>20 months</time_frame>
    <description>Extravasation score rated prospectively by health care professional for each extravasation and 7 days later evolution; description of infused substances, gestational age and age of life at extravasation in patients with severe extravasation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of positive and negative blood cultures in patients suspected of infection according to volume of blood culture</measure>
    <time_frame>20 months</time_frame>
    <description>Prospective record on volume of blood culture and results (positive/negative)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Intensive Care Units, Neonatal</condition>
  <condition>Misadventures to Patients During Surgical and Medical Care</condition>
  <condition>Catheter-related Bloodstream Infection (CRBSI) Nos</condition>
  <condition>Quality of Healthcare</condition>
  <condition>Ventilator Adverse Event</condition>
  <condition>Nosocomial Pneumonia</condition>
  <condition>Immature Newborn</condition>
  <condition>Skin Lesion</condition>
  <condition>Extravasation Injury</condition>
  <condition>Nasal Injury</condition>
  <condition>Intubation Complication</condition>
  <condition>Medication Administered in Error</condition>
  <condition>IV Catheter Nos Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Cluster A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cluster B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster B. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 8 months. The intervention is implemented during 4 months. The length of the post interventional period is 8 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cluster C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster C. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 12 months. The intervention is implemented during 4 months. The length of the post interventional period is 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Education program for NICU caregivers</intervention_name>
    <description>standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)
implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)
multicenter sharing of strategies to prevent adverse events in the NICU</description>
    <arm_group_label>Cluster A</arm_group_label>
    <arm_group_label>Cluster B</arm_group_label>
    <arm_group_label>Cluster C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Patients hospitalized during the study period in one of the 12 participating Neonatal
             Intensive Care Units

          -  Corrected Gestational age not exceeding 42 weeks +6 days at the time of admission in
             the NICU

          -  Length of hospitalisation in the NICU &gt; 2 days

          -  No parental objection to the anonymous data collection of their newborn(s)' clinical
             data, after written information

        Exclusion Criteria:

          -  More than 42 weeks +6 days of corrected gestational age on admission in the NICU

          -  Length of hospitalization in the NICU &lt; or = 2 days

          -  Parental objection to the anonymous data collection of their newborn(s)' clinical data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Caeymaex, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Creteil, Paris Est University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence Caeymaex, MD, PhD</last_name>
    <phone>+33-1-45175433</phone>
    <email>laurence.caeymaex@chicreteil.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camille Jung, MD, PhD</last_name>
    <phone>+33-1-45175433</phone>
    <email>camille.jung@chicreteil.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Strasbourg Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Astruc, MD</last_name>
      <email>Dominique.Astruc@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Astruc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <state>Auvergne Rhône Alpes</state>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leila Marcus, MD</last_name>
      <email>LMarcus@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Leila Marcus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice Cneude, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille Jeanne de Flandres</name>
      <address>
        <city>Lille</city>
        <state>Hauts de France</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Olivier, MD</last_name>
      <email>Damien.OLIVIER2@CHRU-LILLE.FR</email>
    </contact>
    <contact_backup>
      <last_name>Laurent Storme, MD, PhD</last_name>
      <email>Laurent.STORME@CHRU-LILLE.FR</email>
    </contact_backup>
    <investigator>
      <last_name>Damien Olivier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Flamein Ballay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Creteil</name>
      <address>
        <city>Creteil</city>
        <state>Ile de France</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Caeymaex, MD PhD</last_name>
      <phone>+33664095607</phone>
      <email>laurence.caeymaex@chicreteil.fr</email>
    </contact>
    <contact_backup>
      <last_name>Camille Jung, MD PhD</last_name>
      <email>camille.jung@chicreteil.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Durrmeyer, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice Decobert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bicêtre, APHP</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <state>Ile de France</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nolwenn Lesache, MD</last_name>
      <email>nolwenn.lesache@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Nolwenn Lesache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré, APHP</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Baud, MD PhD</last_name>
      <email>olivier.baud@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Ali Bilal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Biran, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Baud, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Poissy</name>
      <address>
        <city>Poissy</city>
        <state>Ile de france</state>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radia Remichi, MD</last_name>
      <email>radia_remichi@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pascal Boileau, MD PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Radia Remichi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Boileau, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Pontoise René Dubos</name>
      <address>
        <city>Pontoise</city>
        <state>Ile de france</state>
        <zip>95000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darina Todorova, MD</last_name>
      <email>darina.todorova@ch-pontoise.fr</email>
    </contact>
    <investigator>
      <last_name>Darina Todorova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saïd Merbouche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Delafontaine</name>
      <address>
        <city>St Denis</city>
        <state>Ile de france</state>
        <zip>93210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Bolot, MD</last_name>
      <email>pascal.bolot@ch-stdenis.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Boileau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cecile Alioux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Guillois, MD, PhD</last_name>
      <email>guillois-b@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard Guillois, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <state>Pays de la Loire</state>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Le Bouedec, MD</last_name>
      <email>StLeBouedec@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Stephane Le Bouedec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand Leboucher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice Archet</name>
      <address>
        <city>Nice</city>
        <state>Provence Alpes Cote d'Azur</state>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Casagrande-Magne, MD</last_name>
      <email>casagrande-magne.f@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gwenn-Marie Verzat, MD</last_name>
      <email>verzat.gm@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Florence Casagrande-Magne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenn Marie Verzat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Sharek PJ, Horbar JD, Mason W, Bisarya H, Thurm CW, Suresh G, Gray JE, Edwards WH, Goldmann D, Classen D. Adverse events in the neonatal intensive care unit: development, testing, and findings of an NICU-focused trigger tool to identify harm in North American NICUs. Pediatrics. 2006 Oct;118(4):1332-40.</citation>
    <PMID>17015521</PMID>
  </reference>
  <reference>
    <citation>Sharek PJ. The Emergence of the Trigger Tool as the Premier Measurement Strategy for Patient Safety. AHRQ WebM&amp;M. 2012 May 1;2012(5). pii: 120.</citation>
    <PMID>23667349</PMID>
  </reference>
  <reference>
    <citation>Chedoe I, Molendijk H, Hospes W, Van den Heuvel ER, Taxis K. The effect of a multifaceted educational intervention on medication preparation and administration errors in neonatal intensive care. Arch Dis Child Fetal Neonatal Ed. 2012 Nov;97(6):F449-55. doi: 10.1136/fetalneonatal-2011-300989. Epub 2012 Apr 5.</citation>
    <PMID>22491014</PMID>
  </reference>
  <reference>
    <citation>Dabliz R, Levine S. Medication safety in neonates. Am J Perinatol. 2012 Jan;29(1):49-56. doi: 10.1055/s-0031-1285831. Epub 2011 Aug 22. Review.</citation>
    <PMID>21861251</PMID>
  </reference>
  <reference>
    <citation>Palmero D, Di Paolo ER, Beauport L, Pannatier A, Tolsa JF. A bundle with a preformatted medical order sheet and an introductory course to reduce prescription errors in neonates. Eur J Pediatr. 2016 Jan;175(1):113-9. doi: 10.1007/s00431-015-2607-4. Epub 2015 Aug 15.</citation>
    <PMID>26272253</PMID>
  </reference>
  <reference>
    <citation>Fisher D, Cochran KM, Provost LP, Patterson J, Bristol T, Metzguer K, Smith B, Testoni D, McCaffrey MJ. Reducing central line-associated bloodstream infections in North Carolina NICUs. Pediatrics. 2013 Dec;132(6):e1664-71. doi: 10.1542/peds.2013-2000. Epub 2013 Nov 18.</citation>
    <PMID>24249819</PMID>
  </reference>
  <reference>
    <citation>Smulders CA, van Gestel JP, Bos AP. Are central line bundles and ventilator bundles effective in critically ill neonates and children? Intensive Care Med. 2013 Aug;39(8):1352-8. doi: 10.1007/s00134-013-2927-7. Epub 2013 Apr 25. Review.</citation>
    <PMID>23615702</PMID>
  </reference>
  <reference>
    <citation>Schulman J, Stricof R, Stevens TP, Horgan M, Gase K, Holzman IR, Koppel RI, Nafday S, Gibbs K, Angert R, Simmonds A, Furdon SA, Saiman L; New York State Regional Perinatal Care Centers. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics. 2011 Mar;127(3):436-44. doi: 10.1542/peds.2010-2873. Epub 2011 Feb 21.</citation>
    <PMID>21339265</PMID>
  </reference>
  <reference>
    <citation>Casanova D, Bardot J, Magalon G. Emergency treatment of accidental infusion leakage in the newborn: report of 14 cases. Br J Plast Surg. 2001 Jul;54(5):396-9.</citation>
    <PMID>11428769</PMID>
  </reference>
  <reference>
    <citation>Collins CL, Barfield C, Horne RS, Davis PG. A comparison of nasal trauma in preterm infants extubated to either heated humidified high-flow nasal cannulae or nasal continuous positive airway pressure. Eur J Pediatr. 2014 Feb;173(2):181-6. doi: 10.1007/s00431-013-2139-8. Epub 2013 Aug 18.</citation>
    <PMID>23955516</PMID>
  </reference>
  <reference>
    <citation>Farquhar C, Armstrong S, Kim B, Masson V, Sadler L. Under-reporting of maternal and perinatal adverse events in New Zealand. BMJ Open. 2015 Jul 23;5(7):e007970. doi: 10.1136/bmjopen-2015-007970.</citation>
    <PMID>26204910</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Dr Caeymaex Laurence</investigator_full_name>
    <investigator_title>Dr, PhD</investigator_title>
  </responsible_party>
  <keyword>Adverse event</keyword>
  <keyword>Neonatal Intensive Care Unit</keyword>
  <keyword>Catheter-related Bloodstream Infection (CRBSI) nos</keyword>
  <keyword>Extravasation injury</keyword>
  <keyword>Medication error</keyword>
  <keyword>Central venous catheter complication</keyword>
  <keyword>Unprogrammed extubation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

